Stay updated with breaking news from Science Summit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sneha Phadke, DO, MPH, expands on the investigation of trastuzumab deruxtecan as a possible treatment option for patients with HER2-positive breast cancer who have high-risk residual disease following neoadjuvant systemic therapy.
Kari Wisinski, MD, highlights the use of oral selective estrogen receptor degraders and CDK4/6 inhibitors in the treatment of patients with hormome receptor–positive/HER2-negative breast cancer, the growing role of antibody-drug conjugates across the breast cancer spectrum, and ongoing research taking place at Carbone Cancer Center.
Hemant S. Murthy, MD, emphasizes the importance of an accelerated manufacturing process for CAR T-cell therapy, discusses the use of CAR T-cell therapy in older and frail patients, and highlights toxicity management strategies that have implemented and are under evaluation for patients receiving CAR T-cell therapy.
The events section is a resource for health care providers to register for upcoming live events focused on cancer and treatment. Read more at OncLive.
Lubna Chaudhary, MD, MS, discusses the ongoing investigation and utilization of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and compared this agent’s efficacy with that of trastuzumab emtansine.